Cell Contact-dependent Functional Selectivity of β2-Adrenergic Receptor Ligands in Stimulating cAMP Accumulation and Extracellular Signal-regulated Kinase Phosphorylation*

Received for publication, September 30, 2011, and in revised form, January 9, 2012. Published, JBC Papers in Press, January 12, 2012, DOI 10.1074/jbc.M111.301820

Ali I. Kaya,‡,§ H. Ongun Onaran,§ Gülnihal Özcan,‡ Caterina Ambrosio,§ Tommaso Costa,§ Sezen Balli,‡ and Özlem Üğur‡,§

From the ‡Department of Pharmacology and the §Molecular Biology and Technology Research and Development Unit, Ankara University, Faculty of Medicine, 06100 Ankara, Turkey, and the ‡Department of Pharmacology, Istituto Superiore di Sanità, 00161 Rome, Italy

Background: β2-Adrenergic receptor (β2-AR) mediates cAMP accumulation and ERK phosphorylation via different transducers. Some β2-AR ligands selectively activate cAMP and ERK responses in HEK-293 cells. Selectivity is cell contact-dependent. β2-AR stimulates ERK phosphorylation by cAMP-dependent and G1/Gq-mediated pathways. Cell contact inhibits the cAMP-dependent pathway. Cell adherence/contact is an important modulatory factor in biased signaling by GPCR ligands.

Results: Some β2-AR ligands selectively activate cAMP and ERK responses in HEK-293 cells. Selectivity is cell contact-dependent. β2-AR stimulates ERK phosphorylation by cAMP-dependent and G1/Gq-mediated pathways. Cell contact inhibits the cAMP-dependent pathway.

Conclusion: β2-AR ligands selectively activate cAMP and ERK responses in HEK-293 cells. Selectivity is cell contact-dependent. β2-AR stimulates ERK phosphorylation by cAMP-dependent and G1/Gq-mediated pathways. Cell contact inhibits the cAMP-dependent pathway.

Significance: Cell adherence/contact is an important modulatory factor in biased signaling by GPCR ligands.

Activation of β2-adrenergic receptor (β2-AR) leads to an increase in intracellular CAMP and activation of ERK. These two signals are activated by the interaction of the receptor with different transducer partners. We showed that the intrinsic activities of β2-AR ligands for stimulating CAMP production and ERK phosphorylation responses in HEK-293 cells were not correlated. The lack of correlation resulted mainly from the discrepancy between the intrinsic activities of two groups of ligands for these two responses: The first group consisted of clenbuterol, cimaterol, procaterol, and terbutaline which acted as full agonists for CAMP production but displayed very weak effect on ERK phosphorylation. The second group comprised adrenaline and noradrenaline which displayed higher intrinsic activity for the ERK phosphorylation than for the CAMP response. Thus, both groups behaved as functionally selective ligands. The functional selectivity of the first group was observable only in adherent cells when confluence was approximately 100%. When cell-cell contact was minimized either by decreasing the density of the adherent cells or by bringing the cells into suspension, the first group of ligands gained the ability to stimulate ERK phosphorylation without a change in their effect on CAMP production. In contrast, selectivity of the second group was independent of the adherence state of the cells. Our results show that the inherent “bias” of ligands in coupling a G protein-coupled receptor to different transducers may not always be revealed as functional selectivity when there is a “cross-talk” between the signaling pathways activated by the same receptor.

The signal transduction mechanism of G protein-coupled receptor (GPCR) systems has long been explained by a linear signal flow scheme in which activation of one type of receptor activates one type of G protein, which, in turn, usually activates one effector (1, 2). Accordingly, receptors have been classified as G1, G2, or G3-coupled depending on the type of G protein they activate. Receptor ligands, on the other hand, have been categorized as agonists, antagonists, or inverse agonists according to their ability to activate (or inactivate) the signal pathway associated with their target receptor. However, it gradually became evident in the past 15 years that one type of receptor can in fact activate branching pathways by interacting with more than one signaling partner (3), including more than one type of G protein (see Ref. 4 and references therein). It is now a widely appreciated phenomenon that receptor ligands can selectively activate these signaling pathways, provided that the branching occurs at the level of receptor-transducer interaction (for a review, see Ref. 5). Thus, a ligand that is an agonist in terms of a signaling pathway may behave as an antagonist for another pathway associated with the same receptor. Identification of this phenomenon, named as functional selectivity (6), is an important development in pharmacology because it provides a new conceptual framework for understanding both the drug effects (and side effects) and the molecular mechanisms of receptor activation.

β2-Adrenergic receptor (β2-AR) is a prototypical G1-coupled receptor that mediates intracellular CAMP increase by activating G1 (7). Hence, efficacy assignment to β2-AR ligands has
been based on the ability of the ligands to activate adenyl cyclase. Relatively more recently, it has been shown that β₂-AR could also mediate extracellular signal-regulated kinase (ERK) activation (8–10). Although the signaling pathway(s) that couple β₂-AR to ERK activation have not been fully understood, strong experimental evidence suggests that the signal is initiated upon the interaction of the activated receptor, in addition to Gₛ, with Gᵢ (10, 11), Src (12), and/or arrestin (11) proteins. As such, β₂-AR-induced cAMP and ERK responses constitute an excellent example for the signal branching at the level of receptor-transducer interaction. Available data concerning the functional selectivity of β-AR ligands suggest that some ligands may selectively activate these two responses, as they behave as antagonists or inverse agonists in terms of cAMP response but as agonists in terms of ERK activation (13, 14). However, a detailed screening of β₂-AR ligands for their efficacy in ERK phosphorylation response has not yet been reported.

The above mechanisms of β₂-AR-initiated ERK activation set aside, intracellular cAMP itself is known to induce or inhibit ERK phosphorylation, depending on the cell type (15–17). To explain such opposite effects, Vossler et al. proposed a model wherein cAMP causes a Rap 1-mediated ERK phosphorylation in cells that express 95-kDa isoform of B-Raf, but inhibits Ras-mediated ERK phosphorylation in cells that lack the B-Raf isoform (16). However, heterologous expression of B-Raf did not always restore the cAMP-induced ERK activation in cells lacking the relevant protein (17). Therefore, mechanisms underlying the cell type-dependence of cAMP-mediated ERK phosphorylation remain unclear. Irrespective of the mechanism(s) involved, in those cells where cAMP is a sufficient signal for ERK phosphorylation, all β₂-AR ligands that increase intracellular cAMP are expected to cause ERK phosphorylation as well. Surprisingly, however, we observed that some β₂-AR ligands that are strong agonists for intracellular cAMP accumulation were unable to induce ERK phosphorylation in HEK-293 cells, a cell line in which cAMP analogs or forskolin, a direct stimulator of adenyl cyclase, have been shown to cause phosphorylation of ERK (18, 19). We also observed that ligands displayed this “functional selectivity” conditionally, depending on the adherence state of the cells. Here, we present a detailed analysis of the β₂-AR ligand efficacies in terms of cAMP accumulation and ERK phosphorylation responses in different adherence conditions and propose a potential mechanism for the conditional nature of the functional selectivity that ligands display.

EXPERIMENTAL PROCEDURES

Materials

Cell culture media and fetal bovine serum (FBS) were purchased from Biological Industries (Kibbutz Beit-Haemek, Israel). Receptor ligands were from either Tocris (Ellisville, MO) or Sigma. Forskolin, dibutyryl-cAMP (db-cAMP), isobutylnethylxanthine, MTT, myristoylated protein kinase A inhibitor peptide (myr-PKI) and pertussis toxin (PTX) were from Sigma. Complete Mini protease inhibitors were from Amersham Biosciences. Primary and HRP-conjugated secondary antibodies, enhanced chemiluminescence substrate, siRNAs targeting the α and β catalytic subunits of PKA (sc-36240 and sc-39158, respectively), and control siRNA (sc-37007) were from Santa Cruz Biotechnology (Santa Cruz, CA). Lipofectamine 2000™ was from Invitrogen.

Cell Culture

HEK-293 cells that stably over express β₂-AR were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with penicillin (100 units/ml), streptomycin (100 μg/ml), and 10% (v/v) FBS, at 37 °C in a humidified atmosphere of 5% CO₂. The expression level of β₂-AR in this stable clone is 30 pmol/mg membrane protein as assessed by 125I-cyanopindolol binding in membrane preparations.

ERK Phosphorylation Assay

Adherent Cells—Unless indicated otherwise, assay was conducted with confluent cells in uncoated 6-well plates (Greiner Bio-One, Frickenhausen, Germany). On the day of the experiment, cells were washed twice with serum-free DMEM and incubated in the same medium at least for 2 h. The assay was initiated by adding the indicated ligands or stimulants at 37 °C. At the end of the incubation, medium was removed, cells were scraped into 100 μl of ice-cold lysis buffer (1% Nonidet P-40, 0.2 mM Na(VO₄), and protease inhibitor mix in PBS) and lysed on ice for 15 min. Lysates were cleared by centrifugation at 10,000 × g for 5 min.

Suspended Cells—On the day of experiment, cells grown to confluence in culture flasks were washed twice with serum-free DMEM and incubated in the same medium at least for 2 h. Cells were then detached by EDTA (1 mM, in PBS), pelleted, resuspended in serum-free DMEM at a density of 3 × 10⁶ cells/ml, and distributed to 96-well ultralow binding plates (Corning) in 100 μl. After a 30–40-min resting period, the assay was initiated by adding the receptor ligands or stimulants (50 μl) and stopped by adding 4 × ice-cold lysis buffer (50 μl). Lysates were cleared by centrifugation at 10,000 × g for 5 min.

The effect of PTX on ERK phosphorylation responses were assessed in cells that were incubated overnight with PTX (100 ng/ml) in serum-free medium. In some experiments, cells were preincubated with H89 (10 μM) or myr-PKI (30 μM) for 20 min in serum-free medium at 37 °C.

For both the adherent and the suspended cells, a time-dependent ERK phosphorylation experiment typically involved four to eight ligands one of which was always isoproterenol. Peak ERK phosphorylation responses induced in 3 min were assessed in parallel for all 16 ligands, forskolin and db-cAMP at least in three independent experiments run in duplicate. Isoproterenol was used in all experiments as the control ligand to assess the daily performance of the cells in terms of ERK phosphorylation response. Responses induced by ligands (or forskolin or db-cAMP) were normalized with that induced by isoproterenol in the parallel experiment to minimize the interexperimental variation.

Immunoblotting

Samples of equal volume from the cleared lysates were separated on 10% SDS-PAGE, transferred to PVDF membranes, and immunoblotted using first an antibody specific for the phos-
Conditional Functional Bias of \(\beta_2\)-Adrenoceptor Ligands

phosphorylated forms of ERK1/2 (pERK). After stripping, membranes were re-probed by an ERK2-specific antibody to assess the total ERK (tERK) amounts in the samples. Protein bands were detected using appropriate HRP-conjugated secondary antibodies and enhanced chemiluminescence as described by the manufacturer. A CCD camera system and an image analysis software (AIDA; Raytest, Straubenhardt, Germany) were used for the densitometric analysis of the protein bands. Band densities in pERK blots were corrected with the tERK densities in the corresponding samples. When multiple gels were used to run the samples of a single experiment, a reference sample was run on each gel, analyzed for pERK and ERK densities, and used as a standard to minimize the potential intrablot variation.

**Determination of cAMP Accumulation in Intact Cells**

**Adherent Cells**—Cells were seeded in 96-well plates (~4 × 10⁴ cells/well) the day before the experiment. On the day of experiment, cells were washed once with serum-free DMEM and incubated in the same medium for at least 2 h.

**Suspended Cells**—On the day of experiment, cells grown to confluence in culture flasks were washed once with serum-free DMEM and incubated in the same medium at least for 2 h. Cells were then detached by EDTA (1 mM, in PBS), pelleted, resuspended in serum-free DMEM at a density of 4 × 10⁵ cells/ml, and distributed to 96-well plates in 100 µL. Both the adherent and the suspended cells were incubated with the receptor ligands for 3 min before the assay. The assay was started by the addition of isobutylmethylxanthine (1 mM) and terminated after 5 min by the addition of HCl at a final concentration of 0.1 N. The amount of cAMP formed was measured by radioimmunoassay as described before (20). Cyclic AMP accumulations were corrected with the cell viability determined by MTT assay in cells seeded (adherent cells) or suspended and preincubated in exactly the same conditions with the cells used in the parallel cAMP assay.

**siRNA Transfection**

Transfections were performed according to the method described by Liu et al. (21). Cells at a confluence of 70% were transfected in 6-well plates with siRNAs targeting \(\alpha\) and \(\beta\) catalytic subunits of PKA (100 pmol/well, each) and nontargeting siRNA (200 pmol/well), using Lipofectamine 2000, according to the recommendations of the manufacturer. After a 6-h incubation, transfection medium was replaced with DMEM containing 5% FCS. Transfection was repeated the following day, using the same amounts of siRNAs. One well of cells was split into 8 wells of 24-well plates at the 24th h and used for the ERK phosphorylation assay on the 48th h of the second transfection. Expression levels of PKA subunits were checked in transfected cell lysates by immunoblotting, using antibodies that specifically recognize \(\alpha\) or \(\beta\) catalytic subunits of PKA.

**Bioluminescence Resonance Energy Transfer Assay of \(\beta_2\)-AR-G Protein and \(\beta_2\)-AR-Arrestin Interactions**

The intrinsic activities of \(\beta_2\)-AR ligands for promoting receptor-G protein or receptor-arrestin coupling were measured by bioluminescence resonance energy transfer. G protein interaction was determined in membrane preparations, whereas the arrestin interaction was recorded in intact cells, using HEK-293 cells co-expressing the luminescent \(\beta_2\)-AR-Rluc and either RGFP-\(\beta_2\) or RGFP-\(\beta\)-arrestin2, as described in detail previously (22). To compare the extent of receptor-arrestin interaction between adherent cells and suspensions, cells (300,000 cells/well) were either seeded in 96-well plates 24 h prior to the assay (adherent state) or added as freshly prepared suspension to each well. In both cases, cells were preincubated for 3 min with 5 µM coelenterazine before the addition of various concentrations of the ligands. After 5 min of further incubation, luminescence was counted in a plate luminometer (VICTOR light; PerkinElmer Life Sciences), and the bioluminescence resonance energy transfer ratio was determined as described (22).

**Statistical Analysis**

We used different variants of Student’s \(t\) statistics whenever appropriate. Pearson’s correlation coefficient was used to measure the association between different variables. We considered \(p < 0.05\) statistically significant.

**RESULTS**

We screened the intrinsic activities of 18 \(\beta_2\)-AR ligands in terms of intracellular cAMP accumulation and ERK phosphorylation responses in a HEK-293 cell clone that stably expresses \(\beta_2\)-AR (HEK-\(\beta\) cells). In terms of adenylyl cyclase activation, the set of the \(\beta_2\)-AR ligands used in this study contained (i) inverse agonists ICI-118,551 and timolol; (ii) neutral ligands sotalol, ICI-89406, and propranolol; (iii) partial agonists cyanopindolol, pronethanol, alprenolol, pinodolol, dobutamine, noradrenaline, and dopamine; and (iv) apparent full agonists adrenaline, clenbuterol, terbutaline, cimaterol, propranolol, and isoproterenol.

In HEK-\(\beta\) cells, all ligands that were able to induce ERK phosphorylation produced a typical transient response with a peak at the 3rd min (Fig. 1). We assessed ERK phosphorylation signal at the 3rd min as the measure of the ability of the ligand to produce ERK response. We measured ligand-induced cAMP accumulation in 5 min in intact cells and used the amount of cAMP produced as the measure of the ability of the ligand to activate adenylyl cyclase. In all assays, ligands were used at saturating concentrations.

**Some \(\beta_2\)-AR Ligands Behave Selectively in Stimulating Adenylyl Cyclase Activation and ERK Phosphorylation**

In 70–100% confluent cells, isoproterenol, adrenaline, noradrenaline, and dopamine induced a strong ERK phosphorylation response, whereas procaterol, terbutaline, cimaterol, and clenbuterol, did not or only weakly stimulated ERK phosphorylation (Fig. 1). The ERK responses to the latter four ligands were quite variable among experiments (from none to a small detectable signal). Among the ligands that induced the ERK response, only adrenaline and noradrenaline caused detectable ERK phosphorylation signals in untransfected HEK-293 cells. Both signals were inhibited almost completely by a specific \(\beta_2\)-AR antagonist, ICI-118,551 (Fig. 1B), showing that the contribution of endogenously expressed adrenergic receptor subtypes (other than \(\beta_2\)-AR) to the ERK responses in HEK-\(\beta\) cells was insignificant in the present experimental conditions. Thus,
procaterol, terbutaline, cimaterol, and clenbuterol that are full agonists for increasing cAMP seemed to behave as antagonists in activating ERK, whereas isoproterenol, adrenaline, noradrenaline, and dopamine behaved as agonists for both the cAMP and the ERK phosphorylation responses. Dobutamine, a partial agonist for cAMP production, reproducibly caused a small but significant ERK phosphorylation response, suggesting that it behaved as a partial agonist for both responses (data not shown, but see below). These results showed that the ligand efficacies for cAMP and ERK responses were not correlated and, by definition, indicated that some β₂-AR ligands were functionally selective in terms of adenylyl cyclase activation and ERK phosphorylation.

**cAMP Induces ERK Phosphorylation Conditionally in HEK-β Cells**

Besides pointing to a functional selectivity, the lack of correlation between ligand-induced cAMP production and ERK phosphorylation also implied that the two responses were independent. In other words, cAMP produced by β₂-AR stimulation did not stimulate ERK phosphorylation directly because some of the ligands tested here were not able to stimulate ERK phosphorylation despite their ability to increase intracellular cAMP to a high level. Apparently, the latter observation is inconsistent with the substantial data in the literature showing that forskolin and cAMP analogs are able to stimulate ERK phosphorylation in the HEK-293 cell line. Indeed, forskolin, as well as a cell-permeable cAMP analog db-cAMP, caused ERK phosphorylation in the present experimental system, suggesting that cAMP was able to induce ERK phosphorylation in our hands as well. This result, at first, seemed to suggest that procaterol, terbutaline, cimaterol, and clenbuterol were activating an additional signal that inhibited the cAMP-mediated ERK phosphorylation. However, in the course of the experiments, we noticed a striking variation in the forskolin-induced response (Fig. 2A). We then found out that the variation in forskolin-induced ERK response could be explained almost completely by the variation in cell confluence: the response gradually decreased and eventually ceased as the cell confluence increased and reached 100% (Fig. 2B). Confluence had a small effect on isoproterenol-induced ERK phosphorylation as well, but this effect was insignificant compared with the one on the forskolin response. As expected, the effect of confluence on db-cAMP-induced ERK response was parallel to that on forskolin response (Fig. 2D). These results showed that cAMP could induce ERK phosphorylation in HEK-β cells conditionally, depending on the confluence state of the culture.

An obvious result of the increased cell confluence is the overall increase in the contact surface between cells, or vice versa. Hence, a possible explanation for the modulatory effect of cell confluence on the cAMP-induced ERK response would be the
Conditional Functional Bias of β2-Adrenoceptor Ligands

Starting from 2.5

FIGURE 2. Conditional Functional Bias of β2-AR Ligands Is Lost When cAMP Can Induce ERK Phosphorylation

The above results led to the question as to whether clenbuterol, cimaterol, procaterol, and terbutaline would induce ERK phosphorylation in the conditions where the intracellular cAMP increase was sufficient for ERK activation. Thus, we examined the ligand-induced ERK phosphorylation responses in reduced cell-cell contact conditions. In contrast to the situation in confluent cells, all of the cAMP agonists, including clenbuterol, cimaterol, procaterol, and terbutaline, were indeed able to stimulate ERK phosphorylation in both 40–50% confluent (data not shown, but see below) and in suspended cells (Fig. 3). Thus, clenbuterol, cimaterol, procaterol, and terbutaline, the ligands that behaved as antagonists in terms of ERK phosphorylation in confluent cells, converted into agonists for the same response when the cell-cell contact was reduced either by reducing the confluence or by bringing the cells into suspension. These results showed that clenbuterol, cimaterol, procaterol, and terbutaline were able to induce ERK phosphorylation only when the intracellular cAMP increase could induce ERK phosphorylation. They also indicated that, in confluent cells, adrenaline, noradrenaline, dopamine, and isoproterenol used a cAMP-independent pathway to induce ERK phosphorylation.

We then screened 18 β2-AR ligands for their ability to induce ERK phosphorylation in 100% and 50% confluent and in suspended cells and assessed the ligand-induced ERK phosphorylation at the 3rd min as the measure of ligand intrinsic activity for ERK activation. Intrinsic activities of the ligands in terms of cAMP accumulation response were not affected by the adherence state of the cells. Neither the order nor the absolute magn-
magnitude of intrinsic activities for cAMP responses (except for adrenaline) was significantly different between adherent and suspended cells (Fig. 4). However, this was not the case for the ERK phosphorylation responses. Comparison of the ligand intrinsic activities for cAMP accumulation and ERK phosphorylation responses in fully confluent cells (Fig. 5, top) showed that there were in fact two groups of ligands that displayed functional selectivity in opposite directions: first group (G1 in Fig. 5) was formed by the ligands that acted as strong agonists for the cAMP response but antagonists for the ERK phosphorylation (clenbuterol, cimaterol, procaterol, and terbutaline) whereas the ligands in the second group (G2 in Fig. 5) displayed higher intrinsic activities for ERK phosphorylation than for cAMP accumulation (adrenaline and noradrenaline). The overall correlation between cAMP accumulation and ERK phosphorylation improved gradually from the adherent (100% confluent) cells to the suspended cells (Fig. 5). This improvement was due mainly to the increase in intrinsic activities of clenbuterol, cimaterol, procaterol, and terbutaline in ERK phosphorylation response in 50% confluent (Fig. 5, middle) and suspended cells (Fig. 5, bottom), whereas the positions of the other ligands in the intrinsic activity scales did not change with the adherence state of the cells. Thus, the functional selectivity of the ligands in the first group was observable conditionally, depending on whether or not cAMP could induce ERK phosphorylation.

FIGURE 3. All ligands that stimulate cAMP accumulation also stimulate ERK phosphorylation in suspended cells. A, HEK-β cells grown to confluence were suspended and stimulated with the indicated ligands for indicated times. After stimulation, cells were lysed, and samples of equal volume from the lysates were analyzed by Western blotting for the phosphorylated and total amounts of ERK as in Fig. 1. The HEK-β cell lysate from the 3rd-min isoproterenol stimulation was run in all gels (except the gel that contains that sample) as a reference and is indicated as C in the figure. Abbreviations and final concentrations for the ligands are the same as in Fig. 1 Shown are the representatives of at least three experiments with similar results.

FIGURE 4. Ligand-induced cAMP accumulation responses in HEK-β cells are not affected by the adherence state. Adherent or suspended cells were incubated with the saturating concentrations of the indicated ligands for 5 min in the presence of 1 mM isobutylmethylxanthine. Reaction was stopped by 0.1 M HCl. Amount of accumulated cAMP was determined by radioimmunoassay and corrected with the number of viable cells as assessed by parallel MTT assays. Experiments were performed in adherent and suspended cells simultaneously. Shown are the mean ± S.E. (error bars) of four independent experiments run in triplicate. Inset, CAMP values in adherent and suspended cells are plotted against each other. Linear regression between the two responses (slope, 0.89; intercept, 0.32) is also shown by the thick line.
Characterization of ERK Phosphorylation Responses

**PTX Sensitivity**—A well established feature of the β₂-AR-mediated ERK phosphorylation by isoproterenol is its inhibition by PTX (10, 11). Therefore, we assessed the PTX sensitivity of ERK phosphorylation responses in adherent (100% confluent) and suspended cells to gain some insight into these apparently different responses. PTX treatment inhibited isoproterenol-, adrenaline-, noradrenaline-, and dopamine-induced ERK phosphorylation observed in confluent cells almost completely: The average inhibition was 79% (Fig. 6A) in this condition. The small but significant ERK phosphorylation response in confluent cells to dobutamine, a partial agonist for cAMP response, was also inhibited by PTX (Fig. 6A). In contrast, ERK phosphorylation responses induced by clenbuterol, cimaterol, proteranol, and terbutaline, as well as by forskolin in suspended cells were resistant to PTX treatment (Fig. 6B). Unlike in the confluent cells, PTX inhibited the isoproterenol-, adrenaline-, noradrenaline-, dopamine-, and dobutamine-induced cAMP response in suspended cells only partially (44% on the average). As noted above, the correlation between the ligand-induced cAMP and ERK responses improved in suspended cells compared with the confluent or 50% confluent cells (see the
FIGURE 6. ERK phosphorylation responses in adherent and suspended cells differ in their PTX sensitivity. A and B, HEK-β2 cells were incubated overnight in serum-free culture medium with or without PTX (100 ng/ml). For the ERK phosphorylation assay in adherent cells (A), the medium was replaced with the serum-free fresh medium 30 min before the ligand stimulation. For the assay in suspension (B), cells were detached by 1 mM EDTA, centrifuged, resuspended in serum-free medium, and let rest for 30 min. Cells were then stimulated with the indicated ligands at final concentrations given in Fig. 1 or with forskolin (10⁻⁵ M) or for 3 min. After stimulation, cells were lysed, and samples of equal volume from the lysates were analyzed by Western blotting for the phosphorylated and total amounts of ERK as in Fig. 1. For each experiment, the basal pERK/ERK value was subtracted from pERK/ERK value of each ligand or forskolin to obtain the stimulated ERK phosphorylation. For the assay in suspension (B), the medium was replaced with the serum-free fresh medium 30 min before the ligand stimulation. For the assay in suspension (B), cells were detached by 1 mM EDTA, centrifuged, resuspended in serum-free medium, and let rest for 30 min. Cells were then stimulated with the indicated ligands at final concentrations given in Fig. 1 or with forskolin (10⁻⁵ M) or for 3 min. After stimulation, cells were lysed, and samples of equal volume from the lysates were analyzed by Western blotting for the phosphorylated and total amounts of ERK as in Fig. 1. For each experiment, the basal pERK/ERK value was subtracted from pERK/ERK value of each ligand or forskolin to obtain the stimulated ERK phosphorylation. ERK phosphorylation signal for each ligand in the absence and the presence of PTX was then corrected with the isoproterenol-induced one in the absence of PTX. Shown are the mean ± S.E. (error bars) of at least four independent determinations run in duplicate. C, PTX-resistant components of the ERK phosphorylation responses for adrenaline, noradrenaline, isoproterenol, dopamine, dobutamine, propanol, cimaterol, terbutaline, and clenbuterol in B were used to replot the graph in lower right panel of Figs. 5 and to calculate the correlation coefficient shown in the figure. ERK phosphorylation data for the other ligands and the ligand-induced CAMP responses are the same as in Fig. 5. * indicates significant difference between mean values, and † indicates significant difference from 1, as assessed by Student’s t test.

It significantly improved further when the PTX-resistant components of the ERK phosphorylation responses in suspended cells were used for the same calculation (Fig. 6C). These results suggest that there are at least two signaling pathways that couple β2-AR stimulation to ERK activation in HEK-β2 cells: (i) the PTX-sensitive pathway that presumably involves Gi/Gs type G proteins, and (ii) the PTX-resistant pathway that seems to be mediated by cAMP and inhibited by cell contact and/or cell adherence. Clenbuterol, cimaterol, propanol, terbutaline, and forskolin seem to induce only the PTX-resistant pathway whereas isoproterenol, adrenaline, noradrenaline, dopamine, and dobutamine can induce both pathways.

Effects of PKA Inhibition—In addition to PTX, isoproterenol-induced ERK phosphorylation in β2-AR-expressing HEK cells has also been shown to be sensitive to H89, a cAMP-dependent protein kinase (PKA) inhibitor (10, 11). This dual sensitivity has led to the currently accepted “switch” hypothesis which suggests that PKA-mediated phosphorylation of β2-AR switches the receptor coupling from Gi to Gs and thereby initiates the ERK signaling (10, 11). Considering the potential nonspecific effects of H89 (23–25), we investigated the putative PKA involvement in the PTX-sensitive ERK phosphorylation responses in confluent cells by complementary approaches: We used two structurally different inhibitors of PKA, i.e. H89 or a specific, cell-permeable PKA inhibitor peptide (myr-PKI), or we knocked down the enzyme by small interfering RNAs targeting the ubiquitously expressed α and β isozymes of PKA catalytic subunits. Isoproterenol and adrenaline were chosen as the representatives of the ligands that stimulate the PTX-sensitive ERK phosphorylation. In accord with previous reports, isoproterenol-induced ERK phosphorylation response was markedly inhibited by H89 in confluent HEK-β2 cells (Fig. 7A). However, this effect was not mimicked by myr-PKI (Fig. 7A), although the latter was fully effective in inhibiting the phosphorylation of cAMP-responsive element-binding protein (CREB), a PKA-mediated effect (Fig. 7B). On the other hand, adrenaline-induced ERK phosphorylation in confluent cells was resistant to both H89 and myr-PKI (Fig. 7A). Moreover, an overall 75% decrease in the expression levels of α and β catalytic subunits of PKA (Fig. 7D), which resulted in a near-complete loss in ligand-induced CREB phosphorylation (Fig. 7E), did not have any effect on the ERK phosphorylation responses to either isoproterenol or adrenaline (Fig. 7C). Thus, among the three interventions that inhibited PKA activity, as judged by their effects on CREB phosphorylation, only H89 was effective in inhibiting the ERK phosphorylation in confluent cells. Furthermore, the latter effect was ligand-dependent. A plausible explanation for these results is that PKA is not involved in β2-AR-mediated, PTX-sensitive ERK phosphorylation and that H89 inhibits isoproterenol-induced ERK response nonspecifically.

Involvement of β-Arrestin—β2-AR-induced ERK phosphorylation has been shown to have a β-arrestin-mediated component that is resistant to PTX (11). Compared with the PTX-sensitive ERK response in confluent cells, a relatively long lasting time course of the ligand-induced ERK response in suspended cells (see Fig. 3) is indeed suggestive of the kinetic pattern reported for the β-arrestin-mediated ERK phosphorylation. Hence, we considered the possibility that the ligand-induced PTX-resistant ERK response in suspended cells might be mediated by β-arrestin. In the context of the present results, either differential coupling of β2-AR to β-arrestin in different adherence conditions or modulation of β-arrestin-mediated ERK phosphorylation by adherence state would explain why the PTX-resistant ERK response could be observed conditionally. To provide more insight to these questions, we measured
β₂-AR-β-arrestin interaction directly in the presence of those ligands that showed differential behavior in terms of ERK phosphorylation in adherent and suspended cells. We used a resonance energy transfer assay to assess 2-AR-arrestin interaction, where 2-AR-rLuc acted as the donor, and GFP-arrestin2 as the acceptor. Fig. 8A shows that ligands such as clenbuterol, cimaterol, and terbutaline induced receptor-arrestin interaction (albeit weak compared with receptor Gs interaction) in adherent cells where they did not induce any ERK phosphorylation at all. This observation may suggest that the efficiency of arrestin-mediated ERK phosphorylation increases in suspended cells compared with the adherent cells, which may then explain the emergence of PTX-resistant ERK responses to clenbuterol, cimaterol, terbutaline, and procaterol in suspended cells. However, the fact that clenbuterol, among the ligands mentioned above, possesses too weak an ability to couple the receptor to arrestin (Fig. 8A) despite its strong action on ERK phosphorylation in suspended cells, weakens the latter possibility. Nevertheless, the possibility that cell detachment increases the ligand-induced 2-AR-arrestin interaction, which in turn compensates for the difference between clenbuterol and the other ligands in terms of receptor-arrestin coupling, still remains. To test the latter possibility, we compared ligand-induced β₂-AR-β-arrestin coupling in adherent and suspended cells using clenbuterol as an extreme case (as explained above) and adrenaline as reference, which behaved

FIGURE 7. Effects of chemical inhibition and knockdown of PKA on the PTX-sensitive ERK phosphorylation are incoherent. A and B, adherent 100% confluent HEK-β cells were incubated in the absence or presence of PKA inhibitors H89 (10 μM) or myr-PKI (30 μM) for 20 min at 37 °C and then stimulated with the indicated ligands for 3 min. After stimulation, cells were lysed, and samples of equal volume from the lysates were analyzed by Western blotting for the phosphorylated amounts of ERK (pERK) or CREB (pCREB) and total amounts of ERK (tERK). For each experiment, the basal pERK/tERK value was subtracted from the pERK/tERK value of each ligand to obtain the stimulated ERK phosphorylation. The stimulated ERK phosphorylation signals in the absence and the presence of PKA inhibitors were then corrected with the isoproterenol-induced one in the absence of the inhibitors. Shown are the mean ± S.E. (error bars) of 4–8 independent experiments. C–E, cells at 70% confluence were transfected twice on consecutive days in 6-well plates with siRNAs targeting α (PKA-Cα) and β (PKA-Cβ) catalytic subunits of PKA (100 pmol/well, each) and nontargeting (NT) siRNA (200 pmol/well). One well of cells was split into 8 wells of 24-well plates at the 24th h and used for the immunoblots in D or the ERK (C) and CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfection. The PKA subunit expression levels (D) and the ERK (C) or CREB (E) phosphorylation assay in at the 48th h of the second transfe...
PTX-resistant ERK responses in the presence of these ligands. Therefore, we concluded that the conditional emergence of the PTX-resistant pathway can be stimulated by all of the $\beta_2$-AR ligands that increase intracellular cAMP, whereas the PTX-sensitive pathway can be activated only by isoproterenol, adrenaline, noradrenaline, dopamine, and dobutamine. The cAMP-mediated pathway is apparently inhibited by cell contact and thus, can be activated only when cell contact is decreased as when the cells are brought to suspension. The $G_i/G_o$-mediated pathway, on the other hand, does not seem to be modulated by cell contact.

Similarly, in adherent and suspended cells in terms of ERK responses. The results of this experiment are shown in Fig. 8B, where no difference was observed in clenbuterol-induced $\beta_2$-AR-β-arrestin coupling in adherent and suspended cells. Therefore, we concluded that the conditional emergence of the PTX-resistant ERK responses in the presence of these ligands can hardly be attributed to a differential involvement of arrestin (if at all) in ERK responses in adherent and suspended cells.

**DISCUSSION**

We showed that the intrinsic activities of $\beta_2$-AR ligands for stimulating cAMP production and ERK phosphorylation responses in HEK cells were not correlated. The lack of correlation resulted mainly from the discrepancy between the intrinsic activities of two groups of ligands for these two responses: The first group consisted of clenbuterol, cimaterol, procaterol, and terbutaline, which acted as full agonists for cAMP production but displayed weak or null effect on ERK phosphorylation. The second group, on the other hand, comprised adrenaline and noradrenaline which displayed higher intrinsic activities for the ERK phosphorylation than for the cAMP response. Thus, both groups behaved as functionally selective ligands. The functional selectivity of the first group was observable only in adherent cells when confluence was approximately 100%.
resistant ERK phosphorylation, depending on the adherence state of the cells. It is this cAMP-mediated component of ERK phosphorylation that is apparently under inhibitory control of cell-cell contact in HEK cells.

In GPCR systems, PTX sensitivity is a distinctive feature of Gi/Go-mediated cellular responses (26). Stimulation by isoproterenol has been shown to cause GTP loading of Gi protein in the membranes of HEK-293 cells overexpressing β2-AR, indicating that the receptor could interact with Gi (10). Using a more direct resonance energy transfer-based method, Casella et al. (22) have shown that isoproterenol-bound β2-AR could indeed interact with PTX-sensitive Gi proteins. Therefore, we may say that in adherent cells, intracellular cAMP increase and PTX-sensitive ERK phosphorylation responses are good indicators of Gi and Gi/Go activation, respectively, by β2-AR stimulation. Hence, the present results suggest that, among the β2-AR ligands that induce Gi coupling, only some are able to couple β2-AR to Gi/Go efficiently. The latter observation provides a clear example of a functional selectivity, a concept based on the fact that different ligands can activate diverse pathways of receptor signaling differentially. Such a ligand-dependent selectivity in receptor signals has generally been accepted as a new pharmacological dimension in GPCR-mediated signaling.

In the present observations, it is worth noting that those ligands that are apparently able to couple the receptor to Gi,Go (in addition to Gs) all contain an intact catechol ring in their structure, whereas those that can activate only Gi do not. Thus, we speculate that the interactions of catecholic OH groups in ligands with the receptor conserved serine and asparagine (Ser-204, Ser-207, and Asn-293) residues (27, 28) may be a critical factor that determines the observed G protein selectivity.

The functional selectivity that β2-AR ligands clearly possess is blunted when the inhibitory control of cell contact on the cAMP-mediated ERK phosphorylation is relieved because in this condition all ligands that are able to increase cAMP also cause ERK phosphorylation, which eventually masks the otherwise existing "bias" of ligands. An important implication of this result is that the inherent bias of ligands in coupling a GPCR to different transducers may not always be revealed as a functional selectivity when there is a cross-talk between the signaling pathways activated by the same receptor. To our knowledge, this is the first example of such a "conditional observability" of functional selectivity.

As noted in the Introduction, the mechanisms of ERK phosphorylation mediated by β2-AR and other Gi-coupled receptors have not been fully understood. In the so-called switch model (10), sensitivity of β2-AR-induced ERK phosphorylation in HEK-293 cells to both PTX and PKA inhibitor H89 has been explained in the context of a single pathway that involves both a Gi/Go type of G protein and cAMP. This model suggests that PKA-mediated phosphorylation of the receptor switches the receptor coupling from Gi to Gs, which, in turn, mediates the ERK phosphorylation. There, an indirect role is attributed to cAMP in ERK phosphorylation, and the ability of forskolin to cause ERK phosphorylation remains unexplained. As discussed above, the present results as a whole cannot be explained by a single pathway. The data, instead, suggest that in HEK cells, β2-AR stimulates ERK phosphorylation by at least two pathways, one of which seems to be directly mediated by cAMP. However, the PTX-sensitive component, which should be cAMP-independent for the reasons explained above, is sensitive to PKA inhibition by H89 in the present experimental system as well. This brings the question as to how a seemingly cAMP-independent response can be sensitive to PKA inhibition. The answer, we believe, lies, in the contradictory results that we obtained by using different strategies to inhibit PKA. Inhibition of PTX-sensitive component of the isoproterenol-induced ERK response by H89 was not mimicked by either mSpyPKI or PKA knockdown, suggesting a nonspecific mechanism rather than PKA inhibition for the effect of H89. Therefore, we may say that PKA is not involved in the PTX-sensitive component of the β2-AR-induced ERK phosphorylation. Furthermore, the observation that the isoproterenol-induced but not the adrenaline-induced ERK phosphorylation was sensitive to H89 suggests that the H89 sensitivity is not a general property of β2-AR-induced ERK phosphorylation but a ligand-dependent phenomenon. The latter observation reproduces the results of previous studies conducted by using isoproterenol (10, 11) or adrenaline (18, 29) and, by itself, is an interesting phenomenon which may worth further investigation.

Cell adherence to the extracellular matrix and contacts among neighboring cells seem to be crucial factors affecting the cellular responses to various stimuli, particularly those that are involved in cell differentiation and proliferation (30). Modulatory effects of cell adherence on ERK activation have been investigated mostly in the context of the canonical receptor tyrosine kinase-Ras-ERK signaling cascade. In those studies, ERK phosphorylation responses to receptor tyrosine kinases were found to be augmented considerably in adherent cells compared with the cells in suspension (31–33). Although the underlying mechanisms are not clear, available data suggest that integrin-dependent cell adherence to extracellular matrix, particularly to fibronectin, increases the efficiency of receptor tyrosine kinase activation (34) and/or signaling between Ras and its downstream effector Raf (32). Although relatively few studies, on the impact of cell adherence on GPCR signaling also indicate an enhancing effect of integrin-mediated adherence on ERK activation responses to various GPCR ligands, including bombesin, lysophosphatidic acid, and ATP (35, 36). Thus, the modulatory effect of cell adherence that we observed for the β2-AR-induced and presumably cAMP-mediated ERK phosphorylation is in the opposite direction of what has generally been reported for receptor tyrosine kinases or other GPCRs, except for the serotonin 5HT1A receptor in LTK fibroblasts (37) and angiotensin ATII receptor in human mesangial cells (38). Moreover, cell-cell contact rather than adherence to extracellular matrix seems to be the modulating factor on β2-AR-induced ERK phosphorylation; first because we did not use any matrix coating in our experiments, and second, but more importantly, decreasing the density of adherent cells and suspending the cells had qualitatively similar effects on ERK responses. Cell-cell contact, in turn, is mediated by the cadherin family of proteins which have also been shown to modulate mitogenic signaling (30, 39, 40). Thus, a cadherin-mediated mechanism rather than an integrin-mediated one seems to be a more likely candidate for modulating the cAMP-mediated
Conditional Functional Bias of β2-Adrenergic Receptor Ligands

component of β2-AR-induced ERK phosphorylation. However, at this point, how and at which point of the pathway the cell–cell contact interferes with the cAMP-mediated ERK activation remains as a novel and interesting question that arises from the present study.

Finally, it would be prudent to mention that all of the results and conclusions of the present study should be considered in the context of the present experimental system. The modulatory effect of cell contact on the cAMP-mediated ERK phosphorylation, and thus the conditional nature of ligand selectivity, may not be observed in all cells, as the cAMP-mediated ERK phosphorylation is well known to be cell type-dependent. Therefore, the results of the present study should not be generalized to other GPCRs or cell systems without further experimentation. However, the latter fact can be considered as a good reason to investigate different GPCRs in different conditions to better understand the mechanisms of GPCR-mediated ERK phosphorylation and regulation of GPCR-mediated signaling in general.

Acknowledgments—We thank Teresa L. Z. Jones and Mehmet Uğur for critical reading of the manuscript.

REFERENCES

1. Gilman, A. G. (1987) G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56, 615–649.
2. Oldham, W. M., and Hamm, H. E. (2006) Structural basis of function in heterotrimeric G proteins. Q. Rev. Biophys. 39, 117–166.
3. Hall, R. A., Preumont, R. T., and Lefkowitz, R. J. (1999) Heparin-binding receptor signaling: beyond the G protein paradigm. J. Cell Biol. 145, 927–932.
4. Kukkonen, J. P., Näsman, J., and Akerman, K. E. (2001) Modeling of promiscuous receptor-G_i/G_o protein coupling and effector response. Trends Pharmacol. Sci. 22, 616–622.
5. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Koblika, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1–13.
6. Kenakin, T. (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol. Sci. 28, 407–415.
7. Rasmussen, S. G., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Koblika, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T., Lyons, J. A., Affrey, M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K., and Koblika, B. K. (2011) Crystal structure of the β2-adrenergic receptor-G protein complex. Nature 477, 549–555.
8. Lazou, A., Bogoyevitch, M. A., Clerk, A., Fuller, S. J., Marshall, C. J., and Sugden, P. H. (1994) Regulation of mitogen-activated protein kinase cascade in adult rat heart preparations in vitro. Circ. Res. 75, 932–941.
9. Crespo, P., Cachero, T. G., Xu, N., and Gutkind, J. S. (1995) Dual effect of β-adrenergic receptors on mitogen-activated protein kinase: evidence for a βγ-dependent activation and a Gα_q-cAMP-mediated inhibition. J. Biol. Chem. 270, 25259–25265.
10. Daaka, Y., Luttrell, L. M., and Lefkowitz, R. J. (1997) Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88–91.
11. Shenoy, S. K., Drake, M. T., Nelson, C. D., Houtz, D. A., Xiao, K., Mabubushi, S., Reiter, E., Preumont, R. T., Lichtarge, O., and Lefkowitz, R. J. (2006) β-Arrestin-dependent, G protein-independent ERK1/2 activation by the β2-adrenergic receptor. J. Biol. Chem. 281, 1261–1273.
12. Sun, Y., Huang, J., Xiang, Y., Bastephe, M., Jüppner, H., Koblika, B. K., Zhang, J. J., and Huang, X. (2007) Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J. 26, 53–64.
13. Galadrim, S., and Bouvier, M. (2006) Distinct signaling profiles of β1- and β2-adrenergic receptor ligands toward adenyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70, 1575–1584.
14. Wissler, J. W., DeWiere, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., and Lefkowitz, R. J. (2007) A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 104, 16657–16662.
15. Stork, P. J., and Schmitt, J. M. (2002) Cross-talk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12, 258–266.
16. Vossler, M. R., Yao, H., York, R. D., Pan, M. G., Rim, C. S., and Stork, P. J. (1997) cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89, 73–82.
17. Qiu, W., Zhan, S., von Lintig, F. C., Boss, G. R., and Pilz, R. B. (2000) Cell type-specific regulation of B-Raf kinase by cAMP and 14–3-3 proteins. J. Biol. Chem. 275, 31921–31929.
18. Keiper, M., Stope, M. B., Szatkowski, D., Böhm, A., Tysack, K., Vom Darge, F., Saur, O., Ouwe Weernek, P. A., Evelin, S., Jakobs, K. H., and Schmidt, M. (2004) Epac- and Ca2+–controlled activation of Ras and extracellular signal-regulated kinases by Gαi-coupled receptors. J. Biol. Chem. 279, 46497–46508.
19. Schmitt, J. M., and Stork, P. J. (2000) β2-Adrenergic receptor activates extracellular signal-regulated kinases (ERK) via the small G protein rap1 and the serine/threonine kinase B-Raf. J. Biol. Chem. 275, 25342–25350.
20. Ugur, O., and Onaran, H. O. (1997) Allosteric equilibrium model explains steady-state coupling of β-adrenergic receptors to adenylate cyclase in turkey erythrocyte membranes. Biochem. J. 323, 765–776.
21. Liu, J., Schuff-Werner, P., and Steiner, M. (2004) Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells. FEBS Lett. 577, 175–180.
22. Casella, I., Ambrosio, C., Gröb, M. C., Molinari, P., and Costa, T. (2011) Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling. Biochem. J. 438, 191–202.
23. Murray, A. J. (2008) Pharmacological PKA inhibition: all may not be what it seems. Sci. Signal. 1, re4.
24. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105.
25. Penn, R. B., Parent, J. L., Pronin, A. N., Panettieri, R. A., Jr., and Benovic, J. L. (1999) Pharmacological inhibition of protein kinases in intact cells: antagonism of β-adrenergic receptor ligand binding by H-89 reveals limitations of usefulness. J. Pharmacol. Exp. Ther. 288, 428–437.
26. Milligan, G. (1988) Techniques used in the identification and analysis of function of pertussis toxin-sensitive guanine nucleotide-binding proteins. Biochem. J. 255, 1–13.
27. Ambrosio, C., Molinari, P., Cotecchia, S., and Costa, T. (2000) Catechol-binding serines of β2-adrenergic receptors control the equilibrium between active and inactive receptor states. Mol. Pharmacol. 57, 198–210.
28. Rosenbaum, D. M., Cherzovev, V., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Koblika, T. S., Choi, H. Y., Yao, X. J., Weiss, W. I., Stevens, R. C., and Koblika, B. K. (2007) GPCR engineering yields high resolution structural insights into β2-adrenergic receptor function. Science 318, 1266–1273.
29. Friedman, J., Babu, B., and Clark, R. B. (2002) β2-Adrenergic receptor lacking the cyclic AMP-dependent protein kinase consensus sites fully activates extracellular signal-regulated kinase 1/2 in human embryonic kidney 293 cells: lack of evidence for Gαi2/Gβγ switching. Mol. Pharmacol. 62, 1094–1102.
30. Aplin, A. E., Howe, A., Alahari, S. K., and Juliano, R. L. (1998) Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50, 197–263.
31. Renshaw, M. W., Ren, X. D., and Schwartz, M. A. (1997) Growth factor activation of MAP kinase requires cell adhesion. EMBO J. 16, 5592–5599.
Conditional Functional Bias of $\beta_2$-Adrenoceptor Ligands

32. Lin, T. H., Chen, Q., Howe, A., and Juliano, R. L. (1997) Cell anchorage permits efficient signal transduction between ras and its downstream kinases. *J. Biol. Chem.* 272, 8849–8852

33. Laakko, T., and Juliano, R. L. (2003) Adhesion regulation of stromal cell-derived factor-1 activation of ERK in lymphocytes by phosphatases. *J. Biol. Chem.* 278, 31621–31628

34. Yarwood, S. J., and Woodgett, J. R. (2001) Extracellular matrix composition determines the transcriptional response to epidermal growth factor receptor activation. *Proc. Natl. Acad. Sci. U.S.A.* 98, 4472–4477

35. Short, S. M., Talbott, G. A., and Juliano, R. L. (1998) Integrin-mediated signaling events in human endothelial cells. *Mol. Biol. Cell* 9, 1969–1980

36. Short, S. M., Boyer, J. L., and Juliano, R. L. (2000) Integrins regulate the linkage between upstream and downstream events in G protein-coupled receptor signaling to mitogen-activated protein kinase. *J. Biol. Chem.* 275, 12970–12977

37. Amber-Cicek, F., Ugur, O., Sayar, K., and Ugur, M. (2008) Cell adhesion modulates 5-HT(1D) and P2Y receptor signal trafficking differentially in LTK-8 cells. *Eur. J. Pharmacol.* 590, 12–19

38. Shikata, Y., Shikata, K., Matsuda, M., Sugimoto, H., Wada, J., and Makino, H. (1999) Signaling transduction pathway of angiotensin II in human mesangial cells: mediation of focal adhesion and GTPase-activating proteins. *Biochem. Biophys. Res. Commun.* 257, 234–238

39. Wheelock, M. J., and Johnson, K. R. (2003) Cadherin-mediated cellular signaling. *Curr. Opin. Cell Biol.* 15, 509–514

40. Qian, X., Karpova, T., Sheppard, A. M., McNally, J., and Lowy, D. R. (2004) E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. *EMBO J.* 23, 1739–1748